Ignite Creation Date:
2025-12-25 @ 2:51 AM
Ignite Modification Date:
2026-02-28 @ 11:27 PM
Study NCT ID:
NCT00061633
Status:
COMPLETED
Last Update Posted:
2019-01-16
First Post:
2003-05-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)
Sponsor:
Cumberland Pharmaceuticals
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
I6424-202a
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Steven Barriere, Pharm.D., Vice President, Clinical and Medical Affairs
Old Organization:
Theravance, Inc.